Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Spruce Biosciences, Inc.NASDAQ: SPRB
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $11.99M fell 17.3% year over year, ahead of the -44.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -17.3% holds above the trailing-twelve-month pace of -44.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 36.51M USD
- Year-over-year change
- -40.2%
- 4-year CAGR
- -3.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.51M | -40.2% |
| FY2024 | 2024-12-31 | 61.06M | -1.6% |
| FY2023 | 2023-12-31 | 62.08M | +31.3% |
| FY2022 | 2022-12-31 | 47.28M | +12.4% |
| FY2021 | 2021-12-31 | 42.07M | — |
Operating Expenses vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 operating expenses of $34.01M is the 5th highest of the 9 companies compared; the peer median is $36.7M.
- Its year-over-year change of -44.2% is the 8th highest of 9, against a peer median of +4.6%.
- Over three fiscal years its annual growth of -8.3% compares with a peer median of -2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Mar 2026 | $52.24M | +6.3% | -0.3% | 159.6% | |
| LTM Jun 2026 | $43.72M | -39.4% | -5.5% | 208.2% | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| Peer median (excluding SPRB) | $36.7M | +4.6% | -2.9% | 497.5% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| Weighted Avg Shares | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
| Weighted Avg Shares (Diluted) | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.